Surgery

Patients with haemophilia A are at a high risk for bleeding complications during and after surgery, requiring the use of prophylactic FVIII at doses higher than what is used during normal prophylaxis.1,2 The aim of haemostatic therapy during the perioperative period is to normalise FVIII levels peri- and post-operatively to maintain normal haemostasis until would healing is complete.3

The efficacy of Nuwiq® (simoctocog alfa) for surgical prophylaxis has been demonstrated in clinical trials and is supported by real-world experience for minor and major surgeries.1,3 There were no serious treatment-related adverse events or development of inhibitors in patients treated with Nuwiq®.3

NuPOWER and NuDIMENSION are two studies exploring the perioperative use of Nuwiq® in distinct haemophilia A populations. NuPOWER focuses on patients receiving emicizumab undergoing major surgery,3 while NuDIMENSION addresses the surgical management of an often overlooked group in clinical research: women and girls with mild to moderate haemophilia A.4

simoctocog-img

Nuwiq® and surgery

Proven haemostatic efficacy during surgery in patients of all ages

antigenic-img antigenic-img antigenic-img

Haemostatic efficacy of
Nuwiq® was rated as
excellent or good in 98% (51 of 52) rated surgeries in
PTPs aged 3–55 years3

The haemostatic efficacy of Nuwiq ®
during surgery has been demonstrated
in prospective clinical trials1 in patients
of all ages with haemophilia A 

circle-img-0

Haemostatic efficacy of
Nuwiq® was rated as
excellent or good in 98% (51 of 52) rated surgeries in
PTPs aged 3–55 years3

circle-img-1
circle-img-2

The haemostatic efficacy of Nuwiq ®
during surgery has been demonstrated
in prospective clinical trials1 in patients
of all ages with haemophilia A 

Nuwiq® and surgery

Well-established safety profile during surgery in patients of all ages

No patients
developed inhibitors3

No treatment-related
adverse events3

antigenic-img antigenic-img antigenic-img
circle-image-0

check-icon No patients
developed inhibitors3

circle-image-2

check-icon No treatment-related
adverse events3

Additional information on the use of Nuwiq® in surgery in different settings can be found in the links below:

References

  • 1

    Lissitchkov T et al. Ther Adv Hematol 2019; 10:2040620719858471;

  • 2

    Lowell AE et al. Curr Anesthesiol Rep 2024; 14:354-65;​

  • 3

    Zozulya N et al. Haemophilia 2018; 24:70-6.​

  • 9

    ClinicalTrials.gov, NCT05935358;

  • 10

    ClinicalTrials.gov, NCT05936580.

Drug safety related information should be reported to at1safetyinformation@octapharma.com If you are a patient, please contact your physician in case of adverse reactions. Please consider the pharmacovigilance data privacy statement if you are reporting drug safety relevant events.

This website is for healthcare professionals only.